Advertisement
U.S. markets closed

BioXcel Therapeutics, Inc. (BTAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8200-0.0600 (-2.08%)
At close: 04:00PM EDT
2.9600 +0.14 (+4.96%)
After hours: 06:28PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close2.8800
Open2.8400
Bid2.8100 x 200
Ask2.8400 x 200
Day's Range2.7900 - 2.9050
52 Week Range1.9100 - 29.5600
Volume335,900
Avg. Volume1,580,057
Market Cap86.226M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-6.1500
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.64
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BTAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioXcel Therapeutics, Inc.
    Technical Assessment: Neutral in the Intermediate-TermWas that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    BioXcel Therapeutics Announces $25 Million Registered Direct Offering

    NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants

  • Simply Wall St.

    BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint

    BioXcel Therapeutics ( NASDAQ:BTAI ) Full Year 2023 Results Key Financial Results Net loss: US$179.1m (loss widened by...

  • GlobeNewswire

    BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

    Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501NEW HAVEN, Conn., March 15, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today reported that the European Patent Office (EPO) granted the Company’s European Patent No. 3,562,486 (the “486 patent”) o